<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637624</url>
  </required_header>
  <id_info>
    <org_study_id>LTC-510-100108-Bahce</org_study_id>
    <secondary_id>CCMO: NL19614.091.07</secondary_id>
    <secondary_id>EudraCT: 2007-002787-95</secondary_id>
    <nct_id>NCT00637624</nct_id>
  </id_info>
  <brief_title>N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy</brief_title>
  <acronym>NAC-PNP</acronym>
  <official_title>A Randomized Double-blind Study of N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy in Patients Treated for (Non)Small Cell Lung Cancer and Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <brief_summary>
    <textblock>
      In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an&#xD;
      anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for&#xD;
      lung cancer with chemotherapy containing cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Cisplatin (CDDP) is a major compound in chemotherapy in patients with non-small cell lung&#xD;
      cancer (NSCLC), small cell lung cancer (SCLC) and malignant mesothelioma. Cisplatin is&#xD;
      associated with a number of side-effects, one of which is neurotoxicity. For a number of&#xD;
      patients this neurotoxicity is a dose-limiting side-effect. At this point no measures are&#xD;
      taken to prevent the occurrence of neurotoxicity during treatment with cisplatin. Recent&#xD;
      studies have shown that the association of anti-oxidants to the treatment with cisplatin has&#xD;
      a neuroprotective effect without loss of anti-tumour efficacy of cisplatin. One of these&#xD;
      anti-oxidants is glutathione (GSH), this is a natural anti-oxidant that is synthesized in all&#xD;
      cells, mainly in the liver and the muscles. This GSH plays a central role in the&#xD;
      pathophysiology (of efficacy and of side-effects) of cisplatin. We want to investigate the&#xD;
      efficacy of N-acetylcysteine (NAC), which serves as a substrate for the synthesis of GSH, in&#xD;
      the prevention of cisplatin-induced neurotoxicity.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
        -  The primary objective is to establish the neuroprotective efficacy of NAC against&#xD;
           cisplatin-induced neurotoxicity. Mainly the sensory neuronal guidance will be assessed&#xD;
           before and after treatment with cisplatin in a group of patients receiving NAC compared&#xD;
           to a control-group receiving placebo. If peripheral neuropathy can't be measured,&#xD;
           neuropathy will be assessed as ototoxicity through measuring audiograms.&#xD;
&#xD;
        -  The secondary objectives are establishing the protective effect of NAC regarding other&#xD;
           cisplatin-induced side-effects such as haematological pathology (anaemia, leucopenia,&#xD;
           thrombopenia, febrile neutropenia), loss of creatinine clearance and occurrence of&#xD;
           liver-chemistry abnormalities. Secondary objectives include also establishing the effect&#xD;
           on tumour response, clinical performance (Karnofsky performance index) and quality of&#xD;
           life.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Monocenter, non-academical teaching hospital, double-blind randomized placebo-controlled&#xD;
      study.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      50 Consecutive patients, who will receive at least 4 cycles of cisplatin in the treatment of&#xD;
      NSCLC, SCLC and malignant mesothelioma, will be admitted, irrespective of the disease stage.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients will be randomized in a placebo-arm and a NAC-arm. They will receive&#xD;
      study-medication (NAC or placebo) intravenously every 3 weeks, each time 6 hours after the&#xD;
      completion of the cisplatin-infusion.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness:&#xD;
&#xD;
        -  Burdens: Patients will have to undergo three electromyographic (EMG) tests, which will&#xD;
           normally take place during the course of the whole treatment, therefore patients will&#xD;
           have to visit the hospital to be measured. To minimize this burden, the EMG-measurements&#xD;
           will be planned on the same day, the patient has to visit the hospital for reasons&#xD;
           regarding his/her regular chemotherapy-treatment. Only surface patch electrodes will be&#xD;
           used (no needle electrodes). All other information will be obtained from the patients'&#xD;
           files (blood samples, physic evaluations, etc) these are considered to be part of the&#xD;
           routines of treatment. When EMG's can not be measured, audiograms will be used, these&#xD;
           audiograms are also part of the routines of treatment, so are not considered an extra&#xD;
           burden. Patients will have to fill in Quality of Life questionnaires.&#xD;
&#xD;
        -  Risks: NAC is a well known drug, used for over thirty years, that is well tolerated. For&#xD;
           intravenous NAC, allergic reactions have been reported. There is also a theoretical&#xD;
           risk, that NAC may reduce anti-tumour efficacy of cisplatin, this risk will be&#xD;
           theoretically ruled out by appropriate dosing of NAC. After inclusion of the first 30&#xD;
           patients an interim analysis will be performed regarding the tumour response.&#xD;
&#xD;
        -  Benefits: NAC will possibly prevent the occurrence of neurotoxicity, improving quality&#xD;
           of life. This may, in turn, result in less probability of dose-reductions and of preterm&#xD;
           arrest of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of peripheral neuropathy: with the peripheral neuropathy score (PNP-score) and the electrophysiological measurements. If no EMG is available, then audiometric measurements will be taken into account.</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>haematological abnormalities</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance.</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver chemistry abnormalities</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofski Performance Score</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Small Cell Lung</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Fluimucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once every 3 weeks intravenous saline fluid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnose is histologically or cytologically proven (NSCLC,SCLC), malignant&#xD;
             mesothelioma (histologically)&#xD;
&#xD;
          -  at least 4 cycles of cisplatin are planned&#xD;
&#xD;
          -  adequate renal function (creatinine clearance as calculated by Cockroft-Gault method &gt;&#xD;
             60 ml/min)&#xD;
&#xD;
          -  Karnofsky performance score &gt; 60 %&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  patient must be able to comply with study measurements i.e. hospital visits for EMG&#xD;
             and QoL assessments&#xD;
&#xD;
          -  age â‰¥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with pre-existing neuropathy&#xD;
&#xD;
          -  patients not willing to stop earlier prescribed NAC&#xD;
&#xD;
          -  patients not willing to stop vitamins E and A above daily advisory dosage&#xD;
&#xD;
          -  uncontrolled metastasis in the central or peripheral nervous system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Idris Bahce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Idris Bahce, M.D.</last_name>
    <phone>+31263788888</phone>
    <phone_ext>3652</phone_ext>
    <email>I.Bahce@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Smit, MD</last_name>
    <phone>+31263788888</phone>
    <phone_ext>3030</phone_ext>
    <email>HSmit@alysis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idris Bahce, MD</last_name>
      <phone>+31263788888</phone>
      <phone_ext>3652</phone_ext>
      <email>I.Bahce@VUmc.nl</email>
    </contact>
    <investigator>
      <last_name>Idris Bahce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>I Bahce</name_title>
    <organization>Rijnstate Hospital</organization>
  </responsible_party>
  <keyword>Acetylcysteine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Antioxidants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

